Short answer
CapsoVision, Inc (CV) filed an 8-K current report with the SEC on March 13, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Total Canon development fee raised to ~$5.1M ($4.1M original + $1M amendment) for CMOS image sensor development.
CapsoVision, Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Total Canon development fee raised to ~$5.1M ($4.1M original + $1M amendment) for CMOS image sensor development
- Amendment triggered by expanded feature specifications; all other original terms unchanged
- Payment structure: $1M upfront cash, remaining ~$4.1M embedded in per-unit pricing under future master purchase agreement
- Strategic dependency: FDA 510(k) clearance for next-gen capsule endoscopy product contingent on Canon delivering sensors to spec
- Minimum purchase commitment under master purchase agreement still required: volume obligation unquantified but binding
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CapsoVision, Inc 8-K filings
Get the next CV 8-K as it lands
Follow CV for push alerts, or ask the research agent what this filing means.